This activity is provided by The France Foundation.

Hoda Z. Abdel-Hamid, MD, FAAN
Associate Professor of Pediatrics and Neurology
Director, Pediatric Neuromuscular Program, UPMC Children's Hospital of Pittsburgh

Perry Shieh, MD, PhD
Professor of Neurology
UCLA Medical Center

Aravindhan Veerapandiyan, MD
Pediatric Neurologist
Arkansas Children’s Hospital

TARGET AUDIENCE
This activity is intended for neurologists, pediatricians, and other health care providers who care for patients with muscular dystrophy.

STATEMENT OF NEED
Until very recently, the only treatment available for DMD was corticosteroids. While clinicians are likely to be well aware of corticosteroids and their utility in the management of DMD, they are less likely to be aware of newer therapeutic options. Given the multisystem involvement of DMD, multidisciplinary management is important, yet this is still not a standard practice. Physicians are likely unaware of mutation-specific targeted therapies presently under development for LGMD. While there are no therapies presently approved for LGMD, several gene therapy trials in clinical stages are underway. These videos share the latest updates in these areas as presented at a recent neuromuscular meeting.

Upon completion of the activity, participants should be able to:

• Review new clinical information on the management of patients with DMD and LGMD presented at major congresses
• Discuss the implication of this information on current clinical practices for clinicians

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures
The following faculty report that they have relevant financial relationships to disclose:

• Dr. Hoda Abdel-Hamid serves on the advisory board for Audentes, AveXis, and Sarepta.
• Dr. Perry Shieh consults for Alexion, AveXis, Biogen, Genentech, and Sarepta. He also serves on the speakers bureau for Alexion, AveXis, Biogen, CSL Behring, Genentech and Grifols.

The faculty listed below report that they have no relevant financial relationships to disclose:

• Dr. Aravindhan Veerapandiyan

ACCREDITATION STATEMENT
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians:
The France Foundation designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses:
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by an educational grant from Sarepta Therapeutics, Inc.

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at https://www.francefoundation.com/privacy.